Central Nervous System Biomarkers Market to Reach USD 11.6 Billion by 2034

Pune, India, November 11, 2025 - The global Central Nervous System (CNS) Biomarkers Market is projected to expand from USD 6.9 billion in 2024 to USD 11.6 billion by 2034, growing at a CAGR of 5.4 %, according to Exactitude Consultancy. Surging prevalence of neurological disorders, breakthroughs in liquid biopsy and imaging biomarkers, and growing adoption of AI-powered diagnostics are fueling the demand for CNS biomarker-based testing and research worldwide.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49947

Key Takeaways
• Market Size (2024): USD 6.9 billion
• Forecast (2034): USD 11.6 billion
• CAGR (2025 - 2034): 5.4 %
• Top Companies: F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, Quanterix Corporation, PerkinElmer Inc., BioMérieux SA, GE Healthcare Technologies Inc., and Merck KGaA.
• Core Applications: Neurodegenerative diseases, psychiatric disorders, traumatic brain injury (TBI), and CNS oncology.

Market Story
The shift toward personalized and precision neurology has placed CNS biomarkers at the center of early diagnosis and treatment monitoring for conditions such as Alzheimer's, Parkinson's, multiple sclerosis, and brain tumors. Advances in genomics, proteomics, and neuro-imaging are enabling clinicians to correlate molecular signatures with disease progression and therapeutic response.

Growing collaboration between biopharma, diagnostics firms, and AI startups is driving innovation in blood-based and CSF biomarker assays, while regulatory agencies are accelerating companion diagnostic approvals to support neuro-targeted drug pipelines.

Market Segmentation
• By Biomarker Type:
o Safety Biomarkers
o Efficacy Biomarkers
o Validation & Exploratory Biomarkers

• By Application:
o Alzheimer's Disease & Dementia
o Parkinson's Disease
o Multiple Sclerosis
o Depression & Schizophrenia
o Traumatic Brain Injury
o CNS Cancer

• By End User:
o Hospitals & Diagnostic Centers
o Academic & Research Institutes
o Pharmaceutical & Biotechnology Companies

• By Region:
o North America: Largest market, driven by high adoption of genetic and imaging biomarkers.
o Europe: Focus on regulatory harmonization for Alzheimer's biomarker validation.
o Asia Pacific: Fastest growth with expanding clinical trial infrastructure in China and India.
o Latin America & MEA: Emerging research centers in neurology and biotech partnerships.

Explore Full Report here: https://exactitudeconsultancy.com/reports/49947/central-nervous-system-biomarkers-market

Recent Developments
• 2025: Roche Diagnostics launched a plasma-based β-amyloid biomarker test for early Alzheimer's screening.
• 2024: Thermo Fisher Scientific introduced high-throughput proteomic panels for CNS drug discovery.
• 2023: Siemens Healthineers rolled out AI-driven PET imaging analytics to quantify amyloid and tau load.
• 2022: Quanterix Corp. expanded its Simoa technology portfolio for ultra-sensitive neurofilament light chain (NfL) detection.

Expert Quote
"CNS biomarkers are revolutionizing how neurological disorders are detected and managed. Integrating digital imaging analytics with molecular data will enable earlier diagnosis and more precise treatment decisions for patients worldwide," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49947

Market Drivers
1. Growing Burden of Neurodegenerative Diseases - Aging populations and early diagnosis needs.
2. Expansion of Precision Medicine and Neuro-Drug Pipelines.
3. Technological Advances in Biomarker Detection - liquid biopsy, AI, and multi-omics integration.
4. Government and Private Funding for Neuro-Diagnostics Research.

Forecast Outlook
Between 2025 and 2034, the CNS biomarkers market will move toward multi-modal diagnostic platforms combining genomic, proteomic, and imaging data. The rise of home-based biomarker testing and digital neurology monitoring will further expand clinical reach and patient accessibility.

Conclusion
The CNS Biomarkers Market is transforming global neurology by making disease detection earlier, faster, and more accurate. As AI integration and biomarker standardization advance, stakeholders across pharma and diagnostics will gain a strategic edge in developing next-generation neurotherapeutics.

This report is also available in the following languages : Japanese (中枢神経系バイオマーカー市場), Korean (중추신경계 바이오마커 시장), Chinese (中枢神经系统生物标志物市场), French (Marché des biomarqueurs du système nerveux central), German (Markt für Biomarker des zentralen Nervensystems), and Italian (Mercato dei biomarcatori del sistema nervoso centrale), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/49947

Related Reports
Oral Disintegrating and Dissolving Film Market
https://exactitudeconsultancy.com/reports/52418/global-oral-disintegrating-and-dissolving-film-market

Drug Delivery Service Market
https://exactitudeconsultancy.com/reports/59764/global-drug-delivery-service-market

Central Nervous System Lymphoma Market
https://exactitudeconsultancy.com/reports/70791/central-nervous-system-lymphoma-market

Pediatric Central Nervous System Tumors Market
https://exactitudeconsultancy.com/reports/71560/pediatric-central-nervous-system-tumors-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.